Search Result

Results for "

subtype selectivity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Adenosine Receptor (3) Adrenergic Receptor (22) Apoptosis (1) Bombesin Receptor (2) Cannabinoid Receptor (2) Carbonic Anhydrase (1) CDK (1) CXCR (1) Cyclophilin (3) Cytochrome P450 (2) DNA/RNA Synthesis (1) Dopamine Receptor (4) ELOVL (1) Endogenous Metabolite (6) Endothelin Receptor (1) Epigenetic Reader Domain (1) ERK (2) Estrogen Receptor/ERR (2) Fluorescent Dye (1) GABA Receptor (10) Glucokinase (1) HDAC (3) Histamine Receptor (8) Histone Acetyltransferase (1) Histone Methyltransferase (1) HIV (1) iGluR (7) IKK (1) Imidazoline Receptor (3) Influenza Virus (2) Integrin (3) Interleukin Related (1) IRAK (1) Isotope-Labeled Compounds (6) JAK (1) JNK (1) Ligands for E3 Ligase (1) LPL Receptor (7) mAChR (9) Melatonin Receptor (4) mGluR (15) Molecular Glues (1) nAChR (15) Neuropeptide FF Receptor (1) Neuropeptide Y Receptor (1) Neurotensin Receptor (3) Opioid Receptor (2) P2X Receptor (2) P2Y Receptor (5) p38 MAPK (1) Phosphodiesterase (PDE) (6) Potassium Channel (7) PPAR (2) Prostaglandin Receptor (5) PROTACs (1) Protease Activated Receptor (PAR) (1) Reference Standards (2) Renin (3) Sigma Receptor (1) Sirtuin (1) Sodium Channel (12) Somatostatin Receptor (10) STAT (1) Thyroid Hormone Receptor (1) TNF Receptor (1) TRP Channel (1) Vasopressin Receptor (1) YAP (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (28) Endocrinology (23) Infection (3) Inflammation/Immunology (33) Metabolic Disease (18) Neurological Disease (106)
Click Chemistry:	Alkynes (1)

198

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103229

Cl-HIBO	iGluR	Neurological Disease
Cl-HIBO is a highly subtype-selective GluR1/2 agonist (EC₅₀=4.7 and 1.7 μM, respectively). Cl-HIBO is a potent AMPA receptor agonist (IC₅₀=0.22 μM). Cl-HIBO has desensitizing properties .

HY-103066

Br-PBTC	nAChR	Neurological Disease
Br-PBTC is a potent, 2/4 subtype-selective positive allosteric modulator of nAChRs (nicotinic acetylcholine receptors) with α2β2, α2β4, α4β2, α4β4, (α4β2)₂α4 and (α4β2)₂β2 EC₅₀ ranges from 0.1-0.6 μM. Br-PBTC acts from the c-tail of an α subunit .

HY-133012

GFB-8438	TRP Channel	Neurological Disease
GFB-8438 is a potent and subtype selective TRPC5 inhibitor, with IC₅₀s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively. GFB-8438 shows excellent selectivity against TRPC6, other TRP family members, NaV 1.5, as well as limited activity against the hERG channel. GFB-8438 protects mouse podocytes from injury induced by protamine sulfate model .

HY-B0374A

Moxonidine hydrochloride BDF5895 hydrochloride	Imidazoline Receptor	Neurological Disease
Moxonidine Hydrochloride is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent.

HY-101308A

MRS2179 tetrasodium hydrate 2 Publications Verification	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .

HY-142723

KCa2 channel modulator 1	Potassium Channel	Neurological Disease
KCa2 channel modulator 1 (compound 2o) is a potent subtype-selective positive modulator of K_Ca2 channel. KCa2 channel modulator 1 potentiates human K_Ca2.3 channels with an EC₅₀ value of 0.19 μM and 0.99 μM on the rat K_Ca2.2 channel subtype .

HY-142735

KCa2 channel modulator 2	Potassium Channel	Neurological Disease
KCa2 channel modulator 2 (compound 2q) is a potent subtype-selective positive modulator of K_Ca2 channel. KCa2 channel modulator 2 exhibits similar potency on the rat K_Ca2.2a and human K_Ca2.3 channel subtypes, with EC₅₀s of 0.64 μM and 0.60 μM, respectively

HY-115764

nAChR agonist 2	nAChR	Neurological Disease
nAChR agonist 2 (compound 8) is a selective alpha4beta2 (α4β2) nAChR agonist (K_d=26 nM) .

HY-150692

Estrogen receptor α antagonist 1	Estrogen Receptor/ERR	Cancer
Estrogen receptor α antagonist 1 (compound 35) is a highly selective antagonist of estrogen receptor α, with IC₅₀s of 0.02, 6.55 and 7.73 μM for estrogen receptor α, estrogen receptor β and MCF-7 cells, respectively. Estrogen receptor α antagonist 1 can be used for the research of cancer .

HY-101308

MRS2179 tetrasodium	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium inhibits platelet aggregation .

HY-142868

ONO-8713	Prostaglandin Receptor	Neurological Disease
ONO-8713 is a selective *prostaglandin E receptor subtype* EP1** antagonist.

HY-123414

GX-936 PF-05196233	Sodium Channel	Neurological Disease
GX-936 (PF-05196233), a potent and *Nav1.7*-subtype selective inhibitor, binds to the activated state of voltage-sensor domain IV (VSD4) .

HY-P1219

Jingzhaotoxin-III β-TRTX-Cj1α	Sodium Channel	Neurological Disease
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype .

HY-125382

L-797591	Somatostatin Receptor	Metabolic Disease
L-797591 is a selective somatostatin receptor subtype 1 (SSTR1) agonist .

HY-B0374

Moxonidine BDF5895	Imidazoline Receptor	Cardiovascular Disease Neurological Disease
Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent.

HY-12811

PF-04856264	Sodium Channel	Neurological Disease
PF-04856264 is a potent and selective Nav1.7 inhibitor, with IC₅₀s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect .

HY-142908

Maximiscin	Endogenous Metabolite	Cancer
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-14319B

Sazetidine A dihydrochloride	nAChR	Neurological Disease
Sazetidine A dihydrochloride is a potent ligand for the α4β2 nAChR, with high binding affinity and selectivity for this subtype. Sazetidine A dihydrochloride exhibits favorable pharmacological properties and may contribute to research targeting nicotinic receptor-related diseases. Sazetidine A dihydrochloride has been mentioned in studies investigating the binding affinity of various analogs, highlighting its importance in understanding the nAChR ligand subtype selectivity .

HY-15831

L-838417-d9	Isotope-Labeled Compounds GABA Receptor	Neurological Disease
L-838417-d₉ is the deuterium labeled L-838417. L-838417 is a subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes .

HY-163317

MMC(TMZ)-TOC	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC can be used for the research of cancer .

HY-12439

ML380 1 Publications Verification	mAChR	Neurological Disease
ML380 is a potent, subtype-selective, and brain-penetrant positive allosteric modulator (PAM) of M5 mAChR, with EC₅₀s of 190 and 610 nM for human and rat M5, respectively. ML380 exhibits moderate selectivity versus the M1 and M3 mAChR subtypes. ML380 could increase the affinity of ACh for the M5 mAChR .

HY-162117

LBG30300	mGluR	Neurological Disease
LBG30300 is a subtype-selective mGlu₂ receptor agonist EC₅₀ 0.6 nM. LBG30300 is blood-brain barrier permeable .

HY-163317A

MMC(TMZ)-TOC TFA	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC TFA has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC TFA targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC TFA can be used for the research of cancer .

HY-157889

ZINC000028464438	HDAC	Cancer
ZINC000028464438 is a selective HDAC11 inhibitor with an IC₅₀ of 3.5 µM. ZINC000028464438 shows almost no inhibition for other HDAC subtypes .

HY-101869

MK-0343 MRK-409	GABA Receptor	Neurological Disease
MK0343 (MRK-409) is an orally bioavailable GABA_A receptor subtype-selective partial agonist. MK0343 is a non-sedating anxiolytic .

HY-14319A

Sazetidine A hydrochloride	nAChR	Neurological Disease
Sazetidine A hydrochloride is a potent ligand for the α4β2 nicotinic acetylcholine receptor, exhibiting high binding affinities and selectivity towards this subtype. Sazetidine A hydrochloride demonstrates promising pharmacological properties that could potentially contribute to the development of therapies targeting nicotinic receptor-related conditions. Sazetidine A hydrochloride has been implicated in studies examining the binding affinities of various analogs, highlighting its significance in understanding subtype selectivity among nAChR ligands.

HY-164964

TRV045	LPL Receptor	Neurological Disease
TRV045 is a selective Sphingosine-1-phosphate subtype 1 receptor agonist with no effect on lymphocyte transport. TRV045 has antiepileptic activity .

HY-101640

TPA 023	GABA Receptor	Neurological Disease
TPA 023 is a GABAA α2/α3 subtype-selective agonist, with K_i of 0.19-0.41 nM.

HY-101254R

Luzindole (Standard) N-0774 (Standard)	Reference Standards Melatonin Receptor	Neurological Disease
Luzindole (Standard) is the analytical standard of Luzindole. This product is intended for research and analytical applications. Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel1b) over MT1 (Mel1a) with Ki values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity .

HY-101254

Luzindole Maximum Cited Publications 12 Publications Verification N-0774	Melatonin Receptor	Neurological Disease
Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel_1b) over MT1 (Mel_1a) with K_i values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity .

HY-19630

ML289 VU0463597	mGluR	Neurological Disease
ML289 (VU0463597) is a potent, selective, and CNS-penetrant mGlu3 (IC₅₀=0.66 μM) negative allosteric modulator. ML289 displays >15-fold selectivity over mGlu2 and is inactive against mGlu5 . ML289 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-108498

L-817818	Somatostatin Receptor	Endocrinology
L-817818 is a potent and subtype-selective agonist of the somatostatin receptor. L-817818 provides a direct approach to defining somatostatin receptor physiological functions

HY-W037331

4,4-Difluorobenzhydrol Bis(4-fluorophenyl)methanol	mAChR	Others
4,4-Difluorobenzhydrol is a precursor of a mAChR antagonist, and its derivative 4,4-Difluorobenzhydrol Carbamate can selectively target the M1 subtype .

HY-107713

PPDA	iGluR	Neurological Disease
PPDA is a subtype-selective NMDA receptor antagonist that preferentially binds to NR2C/NR2D containing receptors .

HY-111271A

L 888607 Racemate	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
L 888607 Racemate is a selective prostaglandin D₂ receptor subtype 1 (DP1) antagonist, with K_is of 132 nM and 17 nM for DP1 and thromboxane A2 receptor (TP), respectively.

HY-117196

GW 9578	PPAR	Metabolic Disease Inflammation/Immunology
GW9578 is a subtype-selective PPARα agonist (EC₅₀s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .

HY-147664

hCAXII-IN-1	Carbonic Anhydrase	Cancer
These compounds show selective inhibition on tumor related subtypes HCA IX and XII, and are also considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.

HY-150727

SIRT5 inhibitor 4	Sirtuin	Cancer
SIRT5 inhibitor 4 (compound 11) is a potent, selective SIRT5 inhibitor with IC₅₀ values of 26.4 and >400μM for SIRT5 and other SIRT subtype, respectively .

HY-15393

VU 0357121	mGluR	Neurological Disease
VU 0357121 is a positive and highly selective mGlu5R allosteric modulator (PAM) with an EC₅₀ of 33 nM. VU 0357121 is inactive or very weakly antagonizing at other mGlu receptor subtypes .

HY-N0584A

Anisodamine hydrobromide 6-Hydroxyhyoscyamine hydrobromide	mAChR	Inflammation/Immunology Cancer
Anisodamine hydrobromide (6-Hydroxyhyoscyamine hydrobromide), a belladonna alkaloid, is a non-subtype-selective muscarinic and a nicotinic cholinoceptor antagonist. Anisodamine hydrobromide shows antioxidant, anti-inflammatory properties .

HY-167824

SSR180711	Endogenous Metabolite	Neurological Disease
SSR180711 is a potent and subtype-selective α7 agonist with activity in Alzheimer's disease and schizophrenia research. SSR180711 can be used to study subtypes of intracerebral hemorrhage associated with cerebral small vessel disease. SSR180711 shows potential in electrophysiological and behavioral studies to evaluate its effects on cognitive function. SSR180711 also has potential for studying cerebrovascular lesions and their effects .

HY-169345

VU6043653	mGluR	Neurological Disease
VU6043653 is a potent, selective and cross the blood-brain barrier *metabotropic glutamate receptor subtype* 5 (mGlu5) negative allosteric modulator with an IC₅₀** value of 325 nM for h mGlu5 .

HY-128770

LY3154207 1 Publications Verification	Dopamine Receptor	Neurological Disease
LY3154207 is a potent, subtype selective, and orally available human dopamine D1 receptor positive allosteric modulator (PAM) with minimal allosteric agonist activity (EC₅₀=3 nM) .

HY-15072

Zonampanel YM 872	iGluR	Metabolic Disease
Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor.

HY-14342

MK-5046 2 Publications Verification	Bombesin Receptor	Metabolic Disease
MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC₅₀ and an EC₅₀ value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .

HY-D0976

NF279	P2X Receptor HIV	Infection
NF279 is a potent selective and reversible P2X1 receptor antagonist, with an IC₅₀ of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC₅₀=1.62 μM), P2X4 (IC₅₀>300 μM). NF279 is a dual HIV-1 coreceptor inhibitor that interferes with the functional engagement of CCR5 and CXCR4 by Env .

HY-116046

GR 196429	Melatonin Receptor	Others
GR 196429 is a melatonin receptor agonist with some selectivity for the MT1 subtype. GR 196429 produces both sleep-promoting effects and alterations of circadian rhythm, as well as stimulating melatonin release in mice .

HY-14312

A85380	nAChR	Neurological Disease
A 85380 is a novel, high affinity neuronal nicotinic acetylcholine receptor (nAChR) agonist. A 85380 exhibits selectivity for the α4β2 nAChR subtypes. A 85380 has a broad-spectrum analgesic profile .

HY-103183

CV1808 2-Phenylaminoadenosine	Adenosine Receptor Endogenous Metabolite	Inflammation/Immunology
CV1808 (2-Phenylaminoadenosine) is a non-selective A2 adenosine receptor (A2 AR) agonist with K_is of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively .

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

Cat. No.	Product Name

HY-L159

Highly Selective Activators Library

1,747 compounds

Agonistic drugs activate or stimulate their receptors, triggering responses that increase or decrease cell activity. The highly selective activators can act on specific biological or molecular targets, while non-selective activators may interfere with multiple targets or targets simultaneously. The highly selective activators reduce the likelihood of these non-specific effects by targeting specific targets, making research more precise and reliable. The Highly Selective Activators Library contains 1,747 compounds, covering multiple targets and subtypes, such as GPCR protein family, Ion channel, multiple kinases, etc. The Highly Selective Activators Library is an effective tool for screening different phenotypes.

HY-L158

Highly Selective Inhibitors Library

5,344 compounds

According to reports, most known kinase inhibitors exert their effects through competitive binding in highly conserved ATP pockets. Although genetic techniques such as RNA interference can inactivate specific genes, most kinases are multi domain proteins, each of which has an independent function. Highly selective inhibitors have higher efficiency than non-selective inhibitors, and the selectivity to the target is at least 100 times higher. Therefore, ensuring the validation of targets with the most selective inhibitors is crucial for a more thorough understanding of the pharmacology of the kinase field. The Highly Selective Inhibitors Library contains 5,344 compounds, covering multiple targets and subtypes, such as GPCR protein family, Ion channel, multiple kinases, etc. The Highly Selective Inhibitors Library is an effective tool for screening different phenotypes

HY-L170

Allosteric Modulators (AMs) Compound Library

212 compounds

An emerging drug design method is based on the secondary binding site effect, where small molecule drugs are designed to bind to secondary binding sites on target biomolecules rather than primary orthomorphic sites. Successful potential drugs (known as allosteric modulators) will be able to bind to allosteric sites and remotely alter (or modify) the conformation of the main orthosteric binding sites of biological targets. Allosteric modulators (AMs) are ligands of proteins that act through binding sites different from natural (orthosteric) ligand sites. AMs are relatively small, more lipophilic, and more rigid compounds. The binding efficacy of AMs with their targets is often slightly lower. AMs are divided into positive AMs (PAMs) and negative AMs (NAMs). AMs are ideal drug targets because they can fine-tune receptor activity while preserving the spatial and temporal signal transduction characteristics of endogenous ligands, resulting in fewer targeted side effects, improved subtype selectivity, and better promotion of biased signal transduction than normal ligands.

MCE designs a unique collection of 212 small allosteric modulators. It is a good tool to be used for research on metabolize, cancer and other diseases.

Cat. No.	Product Name	Target	Research Area

HY-P1221A

ProTx II TFA	Sodium Channel	Neurological Disease
ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal Nav1.7, Nav1.2, Nav1.3 and Nav1.4 with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P1219

Jingzhaotoxin-III β-TRTX-Cj1α	Sodium Channel	Neurological Disease
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype .

HY-P5158

Conopeptide rho-TIA	Adrenergic Receptor	Others
Conopeptide rho-TIA is a peptide derived from the venom contained in the predatory sea snail Conus tulipa, has highly selective and noncompetitive inhibitor at human α_1B-Adrenergic Receptor. Conopeptide rho-TIA acts a competitive inhibitor at human α_1A-Adrenergic Receptor and *α_1D-Adrenergic Receptor. Conopeptide rho-TIA binds to each subtype* and may provide useful information for the development of novel α₁-Adrenergic Receptor subtype-selective drugs** .

HY-P5172

MitTx-alpha	Sodium Channel	Neurological Disease
MitTx-alpha is a subunit of MitTx. MitTx is a potent, persistent, and selective agonist for acid-sensing ion channels (ASICs). MitTx is highly selective for the ASIC1 subtype at neutral pH; under more acidic conditions (pH<6.5), MitTx massively potentiates (>100-fold) proton-evoked activation of ASIC2a channels .

HY-P1221

ProTx II	Sodium Channel	Neurological Disease
ProTx II is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P5010

(D-Arg8)-Inotocin	Vasopressin Receptor	Cardiovascular Disease
(D-Arg8)-Inotocin is a potent, selective and competitive antagonist of vasopressin receptor (V_1aR), with a K_i of 1.3 nM. (D-Arg8)-Inotocin shows more than 3000-fold selectivity for the human V1aR over the other three subtypes, OTR, V1bR and V2R .

HY-P3676

Neuropeptide Y (3-36) (porcine)	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide Y (3-36) (porcine) is an agonist of neuropeptide Y (NPY) receptor subtype Y2, and stimulates feeding in rats. Neuropeptide Y (3-36) (porcine) is a highly Y2 selective ligand compared with nselective Y1/Y2 receptor ligand, Neuropeptide Y 1-36 .

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal Nav1.7, Nav1.2, Nav1.3 and Nav1.4 with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0584A

Anisodamine hydrobromide 6-Hydroxyhyoscyamine hydrobromide	Alkaloids Structural Classification Pyrrole Alkaloids Classification of Application Fields Anisodus tanguticus (Maxinowicz) Pascher Source classification Solanaceae Plants Inflammation/Immunology Disease Research Fields	mAChR
Anisodamine hydrobromide (6-Hydroxyhyoscyamine hydrobromide), a belladonna alkaloid, is a non-subtype-selective muscarinic and a nicotinic cholinoceptor antagonist. Anisodamine hydrobromide shows antioxidant, anti-inflammatory properties .

HY-103183

CV1808 2-Phenylaminoadenosine	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Adenosine Receptor Endogenous Metabolite
CV1808 (2-Phenylaminoadenosine) is a non-selective A2 adenosine receptor (A2 AR) agonist with K_is of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively .

HY-N0584

Anisodamine 6-Hydroxyhyoscyamine	Alkaloids Structural Classification Neurological Disease Classification of Application Fields Other Alkaloids Anisodus tanguticus (Maxinowicz) Pascher Source classification Solanaceae Plants Disease Research Fields	mAChR
Anisodamine (6-Hydroxyhyoscyamine), a belladonna alkaloid, is a non-subtype-selective muscarinic, and also a nicotinic cholinoceptor antagonist. Anisodamine employs in traditional Chinese medicine for many ailments, mainly to improve the microcirculation in states of shock, and also in organophosphate poisoning .

HY-N7225

Yuanhuacine Gnidilatidin	Structural Classification Classification of Application Fields Terpenoids Thymelaeaceae Source classification Diterpenoids Plants Daphne genkwa Sieb. et Zucc. Disease Research Fields Cancer	DNA/RNA Synthesis
Yuanhuacine (Gnidilatidin), a diterpene from Daphne genkwa, is an effective and highly selective inhibitor of the basal-like 2 (BL2) subtype of TNBC. Yuanhuacine can induce G2/M cell cycle arrest and has broad anti-tumor activity. Yuanhuacine is an orally active DNA damaging agent .

HY-111557

YM-254890 5+ Cited Publications	Cardiovascular Disease Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	P2Y Receptor
YM-254890 is a selective G_αq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y₁ signal transduction pathway, with an IC₅₀ value below 0.6 μM .

HY-142908

Maximiscin	Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Maximiscin, a fungal metabolite, induces DNA damage and shows selective cytotoxic activity against a subtype of triple-negative breast cancer.

HY-N0584AR

Anisodamine hydrobromide (Standard)	Alkaloids Structural Classification Pyrrole Alkaloids Anisodus tanguticus (Maxinowicz) Pascher Source classification Solanaceae Plants	mAChR
Anisodamine (hydrobromide) (Standard) is the analytical standard of Anisodamine (hydrobromide). This product is intended for research and analytical applications. Anisodamine hydrobromide (6-Hydroxyhyoscyamine hydrobromide), a belladonna alkaloid, is a non-subtype-selective muscarinic and a nicotinic cholinoceptor antagonist. Anisodamine hydrobromide shows antioxidant, anti-inflammatory properties .

HY-103183R

CV1808 (Standard) 2-Phenylaminoadenosine (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Adenosine Receptor Endogenous Metabolite
CV1808 (Standard) is the analytical standard of CV1808. This product is intended for research and analytical applications. CV1808?(2-Phenylaminoadenosine) is a non-selective A2?adenosine receptor (A2 AR) agonist with Kis of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively .

Cat. No.	Product Name	Chemical Structure

HY-15831

L-838417-d9
L-838417-d₉ is the deuterium labeled L-838417. L-838417 is a subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes .

HY-17416AS

Guanfacine-13C,15N3

Guanfacine- ¹³C, ¹⁵N₃ is the ¹³C and ¹⁵N labeled Guanfacine . Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-B0374S

Moxonidine-d4
Moxonidine-d₄ (BDF5895-d₄) is the deuterium labeled Moxonidine. Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent .

HY-B0391S1

Naftopidil-d5
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .

HY-17416AS1

Guanfacine-15N3,13C2

Guanfacine- ¹⁵N₃, ¹³C₂ is ¹⁵N and ¹³C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-17416S2

Guanfacine-13C,d5 hydrochloride

Guanfacine- ¹³C,d₅ hydrochloride is the deuterium and ¹³C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .

HY-B0391S2

Naftopidil-d7
Naftopidil-d₇ (KT-611-d₇ ) is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .

Cat. No.	Product Name		Classification

HY-123249

HZ166		Alkynes
HZ166 is a GABAA receptor subtype-selective benzodiazepine site agonist with preferential activity at α2- and α3-GABAA receptors. HZ166 shows anti-hyperalgesic effects . HZ166 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks